Company Profile

Axent Biosciences Inc
Profile last edited on: 10/4/2022      CAGE: 8H4J3      UEI: PY6DQ1H6JFU9

Business Identifier: Next generation stem cell therapies
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

521 62nd Street
Oakland, CA 94609
Location: Single
Congr. District: 12
County: Alameda

Public Profile

A recently formed biotech venture spun out of UC Berkeley, Axent Biosciences is structured around development of next generation stem cell therapies to address unmet medical needs in human health. The firm's platform technologies- in stem cell manufacturing and implantation - leverage more that two decades years of stem cell expertise and some 10 years of biomaterials engineering to overcome major bottlenecks in the clinical development pipeline efficiently to provide high quality stem cell therapeutics to large populations of patients in need. Specifically, the effort is to engineer biomaterial technology for two main bottlenecks in the development pipeline for stem cell therapy: manufacturing and implantation.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  David Schaffer -- Founder and President

  Riya Muckom -- Co-Founder & Senior Scientist

  Rocio Sampayo -- Co-Founder Chemical Engineer

Company News

There are no news available.